Co-Chief Editors

Anne S. De Groot, M.D.
Director, TB/HIV Research Lab, Brown Medical School

David Thomas, M.D., J.D.
Professor and Chairman, Department of Surgery, Division of Correctional Medicine, NSU-COM

Deputy Editors

Joseph Bick, M.D.
Chief Medical Officer, California Medical Facility, California Department of Corrections

Renee Ridzon, M.D.
Senior Program Officer, HIV, TB, Reproductive Health, Bill & Melinda Gates Foundation

Bethany Weaver, D.O., M.P.H.
Acting Instructer, Univ. of Washington Center, for AIDS and STD Research

Faculty Disclosure

In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, the faculty of this activity have been asked to complete Conflict of Interest Disclosure forms. Disclosures are listed at the end of articles.

All of the individual medications discussed in this newsletter are approved for treatment of HIV and hepatitis unless otherwise indicated. For the treatment of HIV and hepatitis infection, many physicians opt to use combination antiretroviral therapy, which is not addressed by the FDA.

Supporters

IDCR is grateful for the support of the following companies through educational grants:

• Major Support: Abbott Laboratories, Boehringer Ingelheim and Roche Pharmaceuticals

• Sustaining: Pfizer Inc., Gilead Sciences, Inc., GlaxoSmithKline, Merck & Co., Schering-Plough and ViroLogic.